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Background: Anaplastic thyroid cancer (ATC) is a very aggressive disease and accounts
for over 50% of thyroid-cancer related deaths. mTOR inhibition has shown antitumor activity in ATC. We report our experience treating patients with ATC with
everolimus off-protocol.
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Methods: Patients with confirmed ATC and treated with everolimus at DFCI were
identified and reviewed retrospectively. NexGen sequencing was performed, and
radiologic responses were correlated with mutational profile.
Results: Five patients were treated from 2013 to 2016. Three patients had a response,
which included one patient who achieved a partial response for 27.9 months, and two
patients who had stable disease for 3.7 and 5.9 months, respectively. Genomic analysis
was available in two patients and revealed that the partial responder had mutations
involving the PI3K/mTOR pathway.
Conclusion: Everolimus has anti-tumor activity in ATC, and responses may correlate
with mutations involving the PI3K/mTOR pathway. Further studies are warranted.
Keywords: anaplastic thyroid cancer (ATC), precision medicine, mTOR inhibition in head and neck cancer,
exceptional responder, PI3K mTOR

INTRODUCTION
Anaplastic thyroid cancer (ATC) constitutes only 1–2% of all thyroid cancer cases; however, it is one
of the most lethal types of cancer and has a uniformly poor prognosis with a median survival of 3–5
months (1). It accounts for more than 50% of all thyroid cancer-related deaths due to its aggressive
biology, which is characterized by early hematogenous metastasis. It may arise from differentiated
thyroid cancer TC (2), occurs more frequently in men, and typically afflicts the elderly.
There is currently no standard treatment for metastatic ATC. Weekly taxane with or without
platinum may be used, but these agents have an unknown impact on overall survival (3, 4).
In patients with the activating BRAFV600E mutation, the combination of the BRAF and MEK
inhibitors dabrafenib and trametinib, has recently shown promising activity in ATC (5, 6). Aside
from that group of patients, treatment success has been largely disappointing, highlighting the need
for more effective treatment regimens.
Genomic analysis has found that ATC has a high mutational burden, which contrasts with the
genomic landscape of differentiated thyroid cancer, such as papillary TC, and poorly differentiated
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thyroid cancer (PDTC) (7). In ATC, TERT, TP53, SWI/SNF
subunits, histone methyltransferases, and the PI3K/mTOR/AKT
pathway were frequently altered. Within the PI3K/AKT/mTOR
pathway, mutations in PIK3CA, AKT, mTOR, PTEN,
TSC1, TSC2, and NF1 were more common in ATC than
PDTC, indicating the pathway plays a central role in disease
progression (8).
Rapamycin and its analogs, such as everolimus, are allosteric
inhibitors of the mTOR pathway and specifically inhibit
activation of the mTOR complex 1. Everolimus is FDA
approved to treat various cancers, including breast and renal
cell carcinoma. We have previously treated seven patients with
ATC in an exploratory cohort within a phase 2 study using
everolimus and had two responses (9). Another phase 2 study
using everolimus in patients with thyroid cancer included 6
patients with anaplastic histology, and one partial response was
observed (10). Here, we report our experience with everolimus
given off-protocol in 5 patients with ATC.

FIGURE 1 | Kaplan-Meier survival curve.

and two had unresectable locoregional disease. One patient had
an associated component of papillary thyroid cancer in her tumor
specimen. Two patients received carboplatin and paclitaxel with
radiotherapy prior to starting everolimus, and one patient, who
had papillary thyroid cancer 12 years prior to her ATC diagnosis,
was initially treated with radioactive iodine (RAI), and then a
resection in the thyroid bed for a local recurrence.
All patients started treatment taking 10 mg of everolimus
every day. Due to toxicities such as fatigue and pneumonitis,
patients could receive 10 mg of everolimus every other day.
Overall, patients took everolimus for a median of 5.3 months
(range: 0.8–29.5). Overall, median survival in this cohort was
7.4 months (Figure 1). One patient had a partial response for
27.9 months. This patient’s treatment course was complicated
by mTOR-induced pneumonitis. Initially, the side effects from
everolimus were managed with treatment breaks, but after 12.6
months of treatment, her dose was reduced to 10 mg every
other day. This allowed her to continue with everolimus for
another 16.9 months before her treatment was discontinued.
CT scans revealed that her disease was well controlled at the
time of discontinuation of the drug (Figures 2A–C). Two other
patients had stable disease for 3.7–5.9 months, respectively.
One patient had a mixed response, and another patient had
disease progression.
Genetic analysis demonstrated the BRAFV600E mutation
and two known activating PI3K mutations (PIK3CAE970K and
PIK3CAE542K ) in the partial responder. Additionally, the tissue’s
ATC diagnosis was confirmed (Figures 2D,E). Among the two
patients who had stable disease, sequencing of the primary
tumor revealed the BRAFV600E mutation in one case; no
sequencing could be performed in the other case due to lack of
sufficient material (Table 1). Copy number alterations were also
documented (Figure 3).

MATERIALS AND METHODS
Chart Review
The DFCI’s Institutional Review Board approved this
retrospective case series and chart review for all patients
with ATC who were treated with everolimus off-protocol. All
patients provided written consent, and all patients from 2013 to
2016 were included in this analysis. Investigators assessed tumor
response using radiologic imaging and confirmed them using
the corresponding radiologist reports. Partial responses were
calculated starting from the first scans demonstrating a response,
and stable disease was calculated from the start of everolimus.
Overall survival was calculated from the start of everolimus until
death. All durations were calculated in months.

Genomic Sequencing
Patients who provided written consent for tumor sequencing
had fixed-formalin paraffin embedded slides prepared for total
gDNA extraction. ATC pathology was confirmed prior to
extraction. The sample’s gDNA concentration was quantified and,
if sufficient, underwent library construction, subjected to qPCR,
and analyzed based on the OncoPanel_v1 bait set (Oncopanel),
a database of 275 cancer genes and 91 introns across 30 genes
with known or potential importance in cancer, using an Illumina
Hiseq 2500. Picard tools, which align and de-multiplex read
pairs, and the GATK tool, which localizes realignment, were
used (11, 12).

Tissue Diagnosis
An expert in thyroid pathology (JB) reviewed all ATC cases in this
study and confirmed the diagnoses.

RESULTS

DISCUSSION

Five patients who had ATC and were treated with everolimus offprotocol were identified. Four patients were male and one was
female; the median age at diagnosis was 75 (range: 62–79). Three
patients had distant metastatic disease at the time of diagnosis,
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ATC remains one of the deadliest forms of cancer with no
generally accepted standard of care. In this retrospective analysis,
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FIGURE 2 | Radiologic and histologic imaging of the patient who achieved a partial response (#3).

TABLE 1 | Patient population and treatment results.
1*

2

3*

4*

5

Histology

ATC

ATC

ATC with aPTC

ATC

ATC

Age at diagnosis (y)

75

62

79

78

63

Gender

Male

Male

Female

Male

Male

Stage

M

M

M

LR

LR

Prior treatment

None

Carboplatin and
paclitaxel with radiation

RAI and thyroidectomyc

None

Carboplatin and
paclitaxel with radiation

Mutationsa

N/A

N/A

PIK3CAE542K

BRAFV600E

N/A

PIK3CAE970K
BRAFV600E
Duration prescribed everolimus
(mo)

0.8

1.7b

29.5

5.3d

5.9

Best radiologic response, length
(mo)

PD

MR

PR, 27.9

SD, 3.7

SD, 5.9

Overall survival (mo)

D, 0.8

D, 2.8

D, 39.2

D, 7.4

D, 16.5

*First-line of treatment a only actionable mutations included, b EMR did not capture patient’s final month alive, was not included in analysis, c Treatment for PTC, prior to ATC diagnosis,
d Continued everolimus after radiologic PD, aPTC, associated component of papillary thyroid carcinoma; M, metastatic; LR, locoregional; RAI, radioactive iodine; PD, progressive disease;
MR, mixed response; PR, partial response; SD, stable disease; D, deceased.
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FIGURE 3 | All genomic alterations of patients with sequencing data available.
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we report 5 patients with ATC who underwent palliative
treatment with everolimus. One patient had a partial response
lasting for 27.9 months, and two patients had stable disease
lasting 3.7–5.9 months, respectively. Overall, the median survival
after diagnosis was 7.4 months in this cohort.
Chemotherapy is generally considered marginally effective,
and documented responses to targeted therapies are rare.
Tyrosine kinase inhibitors, which have significant activity in
differentiated thyroid cancer (13–16), have been used with some
success in ATC. In a report of 2 patients treated with Axitinib,
one patient had a PR (17). In a phase II study with sorafenib, 4/10
patients with ATC had disease stability (40%) (18). Additionally,
a multi-center trial found that 2/20 patients had a PR, lasting for
10–27 months, respectively, and 5/20 had SD (19). A single-arm
phase II study using lenvatinib in thyroid cancers, including 17
patients with ATC, reported an objective response rate of 24%
and median OS of 10.6 months (16). In a recent retrospective
study of 5 patients with unresectable ATC treated with lenvatinib,
Koyama et al. found that 3/5 had a PR, 5/5 had SD, and the cohort
had an OS of 165 days (20). Pazopanib, a VEGF inhibitor, has
weak activity in ATC; a mulitinistiutional study of 15 patients
treated with pazopanib monotherapy did not have any confirmed
RECIST responses (21).
Combination therapy with BRAF and MEK inhibitors has
shown anti-tumor activity in ATC. A recently published clinical
trial treating patients with BRAFV600E positive ATC with
dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor)
reported a 69% ORR (11/16) with long-lasting responses (6).
Another BRAF inhibitor, vemurafenib, has had some success (22,
23). In contrast, we have previously reported one patient with a
BRAFV600E and a PIK3CAH1047R mutation who failed to respond
to everolimus or dabrafenib and trametinib, but responded to the
combined regimens (24).
In a prior phase II study, we evaluated everolimus as a
single agent in 7 patients with metastatic ATC (9). Among
these 7 patients, two responded: one achieved an exceptional
response and another had disease stability for 31 months. Both
patients carried mutations involving the PI3K/mTOR pathway;
genetic analysis of the exceptional responder’s tumor revealed a
truncating TSC2 mutation, resulting in loss of negative regulation
of mTOR signaling (25), and the other patient had a mutation
in NF1, a regulator of TSC2 and mTOR, and in PIK3CA and
mTOR (9).
Recent analyses have begun to elucidate the molecular drivers
behind ATC tumorigenesis. TERT, TP53, and PIK3CA appear
to be more frequently mutated than in other forms of thyroid

cancer, including in poorly differentiated thyroid cancer (PDTC),
which may present histologically and clinically similar to ATC.
Sequencing 33 ATC and 84 PDTC tumor samples discovered that
TERT and TP53 mutations have been reported in 73% of cases,
but we did not find any in our samples. Additionally, PIK3CA
mutations were present in 18% of ATC samples, but only in 2%
of PDTCs, and PI3K/AKT pathway abnormalities were found in
39% of ATC samples vs. 11% of PDTC (8).
The partial responder’s tumor was sequenced and revealed
three somatic variants: PIK3CAE542K , a helical domain and
hotspot mutation, PIK3CAE970K , a mutation in the PI3’ kinase
domain, and BRAFV600E , a common mutation in ATC (8, 26).
Tumorigenesis in animal models indicate that activating PI3K
mutations alone are not sufficient to trigger the development
of ATC and therefore frequently occur in combination with
other mutations, such as BRAFV600E . Cell culture data has
demonstrated synergy in ATC when both genes were mutated,
and it is thought that BRAF activation promotes ATC
transformation and PIK3CA drives its growth (27). In our
experience with everolimus from this case series and previously
reported phase II data, PI3K/mTOR activating mutations were
present in all cases with a durable response (9, 24, 25).
Interestingly, ATC rarely arises from differentiated TCs and
form as metastases. In a study including 677 cases of ATC,
only 6 cases demonstrated transformation at the metastatic sites
(0.9%), and this cohort had the worst outcomes (28). The partial
responder’s ATC was first diagnosed after a lobectomy, suggesting
that she had an initially poorer prognosis than the typical patient
with ATC.
Our study has several limitations: although all patients
who underwent treatment with everolimus off-protocol at our
institution were included in this retrospective analysis, the
generalizability of our findings are limited due to the sample size
and sequencing data. The disease’s rarity makes it challenging
to study larger cohorts of patients with ATC. Some patients
did not consent to genetic sequencing or did not have enough
tumor tissue.
This case series adds to the existing evidence that
everolimus has anti-tumor activity in ATC, and responses
may correlate with mutations along the PI3K/mTOR axis.
Further investigation is warranted.
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